Abstract CT074: Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy.
Year: 2019
Type: conference-abstract
Source: Clinical Trials
Authors: Solange Peters, Byoung Chul Cho, Niels Reinmuth, Ki Hyeong Lee, Alexander Luft, Myung-Ju Ahn, Paul Baas, Manuel Cobo Dols, Alexey Smolin, David Vicente, Vladimir Moiseyenko, Scott J. Antonia, Kazuhiko Nakagawa, Sarah B. Goldberg, Edward Kim, Rajiv Raja, Philip Brohawn, Delyth Clemett, Piruntha Thiyagarajah, Urban Scheuring, Feng Liu, Naiyer Rizvi
Institutions: Centre Hospitalier Universitaire Vaudois, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Asklepios Fachkliniken München-Gauting, Chungbuk National University, Chungbuk National University Hospital, Leningrad Regional Cancer Center, Samsung Medical Center, The Netherlands Cancer Institute, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga, Hospital Universitario Virgen Macarena, Moffitt Cancer Center, Kindai University, Yale University, Levine Cancer Institute, AstraZeneca (United Kingdom), AstraZeneca (United States), Columbia University Irving Medical Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4243053597